Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ITOS | US
0.20
2.04%
Healthcare
Biotechnology
30/06/2024
04/10/2024
10.02
9.61
10.07
9.59
Iteos Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448 an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains which is in Phase 1/2 clinical trial as well as used to engage the Fc gamma receptor or Fc"R to activate dendritic cells natural killer cells and macrophages and to promote antibody-dependent cellular cytotoxicity or ADCC activity. Iteos Therapeutics Inc. was founded in 2011 and is headquartered in Watertown Massachusetts."
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
45.3%1 month
103.7%3 months
77.1%6 months
88.2%-
12.56
0.58
0.01
0.01
0.50
1.26
-
-139.26M
365.95M
365.95M
-
-37.92
-88.60
-100.00
-16.80
5.62
12.87
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.88
Range1M
8.04
Range3M
8.54
Rel. volume
0.46
Price X volume
4.46M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Theravance Biopharma Inc | TBPH | Biotechnology | 8.1 | 396.27M | -1.34% | n/a | 24.09% |
Voyager Therapeutics Inc | VYGR | Biotechnology | 7.04 | 383.91M | 20.96% | 21.67 | 13.99% |
Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 10.48 | 379.48M | 3.46% | n/a | 9.95% |
ZVRA | ZVRA | Biotechnology | 7.2 | 378.85M | 1.12% | n/a | 183.10% |
C4 Therapeutics Inc | CCCC | Biotechnology | 5.38 | 373.04M | -0.92% | n/a | 27.69% |
Anika Therapeutics Inc | ANIK | Biotechnology | 24.99 | 369.77M | -0.12% | n/a | 13.35% |
Fate Therapeutics Inc | FATE | Biotechnology | 3.22 | 366.69M | 0.31% | n/a | 25.33% |
Corvus Pharmaceuticals Inc | CRVS | Biotechnology | 5.64 | 352.79M | 6.82% | n/a | 1.37% |
INZY | INZY | Biotechnology | 5.17 | 346.90M | 2.78% | n/a | 49.47% |
Nautilus Biotechnology Inc. | NAUT | Biotechnology | 2.71 | 339.86M | -0.73% | n/a | 13.86% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.50 | 0.76 | Cheaper |
Ent. to Revenue | 1.26 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 0.58 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 77.06 | 74.67 | Par |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 365.95M | 3.73B | Emerging |